The IAB logo The Institute for Applied Biomedicine
Immudel™-gp120: A New Drug to "Cure AIDS" *
  The Institute for Applied Biomedicine is developing a new AIDS drug designed to keep the immune system healthy even in the presence of HIV. Initial test results have been unusually encouraging. We are a not-for-profit biotechnology firm committed to making our drugs accessible as widely as possible.

  • Non-Technical Summary - a non-technical summary of how HIV appears to cause the immune system to fail and how the Institute's drug would restore and maintain the immune system.

  • Pilot Test Results - results of pilot tests to determine whether Immudel™-gp120 has the potential to be safe and effective.

  • Immudel-gp120 Development Plans - how the Institute plans to develop Immudel-gp120.

  • Technical Information - detailed information about Immudel-gp120; review by experts; excerpts from scientific articles; the Institute's Medical Hypotheses article; references.

  • AIDS Information - information about the HIV/AIDS epidemic and current AIDS treatments. Also, links to other websites with information about various aspects of AIDS.

* By "cure AIDS" we mean prevent the collapse of the immune system called AIDS. We do not believe that our drug, or any drug or combination of drugs, is capable of making an HIV-positive person HIV-negative again. (Click here for more information)

© 1997-2008 Institute for Applied Biomedicine. All Rights Reserved. Legal Notices.